About vaccines

Recently, the researchers from the USA, in their study published in the journal EBioMedicine, have conducted a sequence identity comparison and 3D protein structure comparison between the SARS-CoV-2 spike protein-derived peptides/protein and myocarditis-associated antigens and have found no significant enrichment in the frequency of spike-derived peptides similar to myocarditis-associated antigens that could have resulted in adaptive autoimmune responses leading to myocarditis. // 12.1.2022

Key messages: WHO has established the Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) to review and assess the public health implications of emerging SARS-CoV-2 Variants of Concern (VOC) on the performance of COVID-19 vaccines and to provide recommendations to WHO on COVID-19 vaccine composition, as needed. “The TAG-CO-VAC considers that COVID-19 vaccines that have high impact on prevention of infection and transmission, in addition to the prevention of severe disease and death, are needed and should be developed. Until such vaccines are available, and as the SARS-CoV-2 virus evolves, the composition of current COVID-19 vaccines may need to be updated, to ensure that COVID-19 vaccines continue to provide WHO-recommended levels of protection against infection and disease[4] by VOCs, including Omicron and future variants.” // 11.1.2022

A new study discusses the effect of vaccines against COVID-19 on the transmissibility and susceptibility of vaccine recipients to SARS-CoV-2. // 11.1.2022

In a new study, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of COVID-19 and concluded that post-exposure prophylaxis successfully decreased SARS-CoV-2-associated death rates. // 11.1.2022

The current study examines the role of heterologous vaccination, an area that lacks much clarity. // 11.1.2022

Researchers from IQVIA Real-World Solutions have investigated how effective these vaccines are against severe disease. // 11.1.2022

Researchers recently assessed vaccine effectiveness against Omicron and Delta variant-induced infection as well as hospitalization, including among immunocompromised individuals. // 10.1.2022

Researchers compared the characteristics of fully vaccinated and boosted and unvaccinated patients requiring hospitalization for COVID-19. // 10.1.2022

Natural Cycles.” We included U.S. residents aged 18–45 years with normal cycle lengths (24–38 days) for three consecutive cycles before the first vaccine dose followed by vaccine-dose cycles (cycles 4–6) or, if unvaccinated, six cycles over a similar time period. // 5.1.2022

A new study published in The Journal of Infectious Diseases examined if influenza vaccination altered the risk of SARS-CoV-2 infection and clinical outcomes of COVID-19. The study included health care workers (HCWs) from Denmark who were offered influenza vaccination. // 9.1.2022

A new study displays that vaccine breakthrough COVID-19 infections are far less likely to transmit from the index patient to contacts than infections in partially or unvaccinated individuals. // 7.1.2022

We have analyzed BNT162b2 vaccine-induced immune responses in naive subjects and individuals recovered from coronavirus disease 2019 (COVID-19), …

Kuolleista lähes neljä viidestä kuului vähintään neljään riskiryhmään. // 8.1.2022

Researchers investigate the effectiveness of COVID-19 vaccines in individuals at high risk due to their proximity with infected individuals. // 6.1.2022

This report describes risk factors for severe COVID-19 outcome among vaccinated people. // 7.1.2022

In this paper, researchers studied whether the neutralizing immunity produced by Omicron also increases neutralizing immunity of the Delta variant. // 6.1.2022

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol. // 5.1.2022

Memory B cells never forget recurrent viral exposures and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is no exception, according to a new medRxiv* preprint study. // 5.1.2022

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose. // 5.1.2022

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose. // 5.1.2022

A study has demonstrated that antibodies induced by two-dose COVID-19 vaccination or natural infection exhibit very low neutralizing activity against the omicron variant of SARS-CoV-2. // 4.1.2022

A recent study suggests neutralizing antibody responses against variants of concern, including Omicron, differs significantly between vaccinated and naturally infected individuals. The research, posted to the medRxiv* preprint server, focused on vaccinated individuals who are pregnant — an understudied group in COVID-19 research. // 4.1.2022

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies. // 4.1.2022

Published on the preprint medRxiv* server and awaiting peer review, the findings showed that the significant factor behind breakthrough Omicron infections is the timing from vaccination. The time between vaccination and breakthrough infections induced effective or cross-reactive neutralizing antibodies that neutralize Omicron after Alpha or Delta breakthrough infections. // 4.1.2022

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant. // 3.1.2022

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants. // 3.1.2022

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity. // 3.1.2022

// 1.1.2022

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect. // 30.12.2021

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). // 30.12.2021